Search

Xenon Pharmaceuticals Inc

Cerrado

SectorSanidad

62.33 -0.02

Resumen

Variación precio

24h

Actual

Mínimo

60.96

Máximo

62.73

Métricas clave

By Trading Economics

Ingresos

-8.4M

-111M

BPA

-1.11

Empleados

358

EBITDA

420K

-111M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+25.08% upside

Dividendos

By Acuity

Próximas Ganancias

2 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

190M

6.2B

Apertura anterior

62.35

Cierre anterior

62.33

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

287 / 340 Clasificación en Healthcare

Xenon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 ago 2026, 23:01 UTC

Xenon Pharmaceuticals Inc. is trading higher in after-market hours, despite no specific news to explain the move. The stock remains below its 20-day moving average.

15 ago 2026, 00:01 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, though no specific news was identified to explain the movement.

14 ago 2026, 23:01 UTC

Xenon Pharmaceuticals shares are higher in after-market hours, reflecting a modest gain since Friday's close. The stock remains below its 20-day moving average.

13 ago 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are declining, trading below their 20-day moving average amid broader market support, despite rising initial jobless claims.

12 ago 2026, 22:51 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, reflecting notable volatility and fluctuations since Wednesday's close within the one-month trading range.

11 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and subdued trading activity.

10 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market hours, despite earlier pulling back from a session high. No specific news was identified for the movement.

7 ago 2026, 20:06 UTC

News
Social Media

Xenon Pharmaceuticals shares are lower as RBC cuts the price target to $81.00 and the company reports a larger-than-expected Q2 loss of $110.7 million.

6 ago 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. shares are lower today, retracing earlier gains. The stock is trading near the lower end of its one-month range.

5 ago 2026, 23:41 UTC

Xenon Pharmaceuticals Inc. shares are higher in after-market hours amid notable volatility, though no specific news was identified to explain the movement.

4 ago 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are trading lower during after-market hours, breaking a recent trend of higher daily closes since Tuesday.

3 ago 2026, 19:46 UTC

News

Xenon Pharmaceuticals announced equity inducement grants totaling 32,758 share options and 19,013 RSUs. Shares are lower during Monday's session, near the one-month range's low.

31 jul 2026, 23:01 UTC

News

Xenon Pharmaceuticals shares are lower in after-market hours following the announcement of inducement grants for eleven new non-officer employees.

30 jul 2026, 13:36 UTC

Xenon Pharmaceuticals Inc shares are higher in pre-market trading, reflecting a broader market recovery despite rising treasury yields and geopolitical tensions.

29 jul 2026, 21:02 UTC

Xenon Pharmaceuticals Inc. shares are little changed after-market, continuing a trend of three consecutive lower daily finishes amid a broader decline in U.S. equities.

28 jul 2026, 19:16 UTC

Xenon Pharmaceuticals Inc shares are lower today, pulling back from earlier gains amid notable volatility and no specific news to explain the movement.

27 jul 2026, 16:06 UTC

Xenon Pharmaceuticals Inc shares are lower today amid a broader market decline linked to falling crude oil prices and eased geopolitical tensions.

24 jul 2026, 23:31 UTC

Xenon Pharmaceuticals Inc shares are higher in after-market trading, reflecting positive momentum since Friday's close, despite no specific news identified.

23 jul 2026, 23:51 UTC

Xenon Pharmaceuticals Inc shares are lower in after-market hours, continuing a downward trend with no specific news identified to explain the decline.

22 jul 2026, 23:11 UTC

Xenon Pharmaceuticals Inc shares declined in after-market trading amid broader market volatility, influenced by geopolitical tensions and rising crude oil prices.

21 jul 2026, 19:36 UTC

Xenon Pharmaceuticals shares are higher, supported by overall market strength and advances in biotechnology stocks, despite no specific company news identified.

20 jul 2026, 22:02 UTC

Xenon Pharmaceuticals Inc. shares are lower in after-market trading, following notable volatility and no specific news identified. The stock remains above its 20-day moving average.

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

25.08% repunte

Estimación a 12 Meses

Media 78 USD  25.08%

Máximo 90 USD

Mínimo 63 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

12

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

287 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat